Protein Kinase Inhibitors

Kinase Inhibitor

mTOR Inhibitors

mTOR Inhibitor Immunosuppressant

Cytochrome P450 2D6 Inhibitors

Cytochrome P450 3A4 Inhibitors

<section class="Section" data-sectioncode="34089-3"><a name="s11"></a><a name="section-9"></a><h1>11     DESCRIPTION</h1>AFINITOR (everolimus) and AFINITOR DISPERZ (everolimus tablets for oral suspension) are kinase inhibitors.The chemical name of everolimus is (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18- dihydroxy-12-{(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone. The molecular formula is C53H83NO14 and the molecular weight is 958.2 g/mol. The structural formula is:<img alt="everolimus structural formula" src="afinitor-01.jpg"/>AFINITOR for oral administration contains 2.5 mg, 5 mg, 7.5 mg, or 10 mg of everolimus and the following inactive ingredients: anhydrous lactose, butylated hydroxytoluene, crospovidone, hypromellose, lactose monohydrate, and magnesium stearate.AFINITOR DISPERZ for oral administration contains 2 mg, 3 mg, or 5 mg of everolimus and the following inactive ingredients: butylated hydroxytoluene, colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, mannitol, and microcrystalline cellulose.</section>

Afinitor

everolimus 7.5 MG Oral Tablet

everolimus 7.5 MG Oral Tablet [Afinitor]

everolimus 2 MG Tablet for Oral Suspension

everolimus 3 MG Tablet for Oral Suspension

everolimus 5 MG Tablet for Oral Suspension

everolimus 2 MG Tablet for Oral Suspension [Afinitor]

everolimus 3 MG Tablet for Oral Suspension [Afinitor]

everolimus 5 MG Tablet for Oral Suspension [Afinitor]

everolimus

everolimus 10 MG Oral Tablet

everolimus 10 MG Oral Tablet [Afinitor]

everolimus 5 MG Oral Tablet

everolimus 5 MG Oral Tablet [Afinitor]

everolimus 2.5 MG Oral Tablet

everolimus 2.5 MG Oral Tablet [Afinitor]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals

Enroll in Patient Savings Program - Oncology Indications 

PANO Service Request Form: HCP 

PANO Service Request Form: Patient 

Other HCP Resources

Instructions For Use: Tuberous Sclerosis Complex (TSC) Seizure 

Instructions For Use: Tuberous Sclerosis Complex (TSC) - SEGA 

Instructions For Use: Tuberous Sclerosis Complex (TSC)-Renal Angiomyolipoma

Instructions for Use: Advanced HR+, HER-2 Negative Breast Cancer

Instructions For Use: Advanced Renal Cell Carcinoma

Instructions For Use: Advanced Pancreatic Neuroendocrine Tumor (NET)

Instructions For Use: Progressive Nonfunctional GI and Lung Neuroendocrine Tumors (NET)